WilliamDTapMD

Associate Member, Memorial Sloan Kettering Cancer Center

Overview of Dr. Tap

Dr. William Tap is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 17 years. Dr. Tap accepts several types of health insurance, listed below. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(817) 756-7584

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Vanderbilt University Medical CenterResidency, Internal Medicine, 2000 - 2003
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000

Certifications & Licensure

CA State Medical License 2003 - Present
FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2011 - 2024
TN State Medical License 2002 - 2004
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Top Doctors: New York Metro Area Castle Connolly, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Sorafenib and Dacarbazine in Soft Tissue Sarcoma Start of enrollment: 2009 Feb 01
Completed
Phase 2
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Start of enrollment: 2009 Apr 01
Completed
Phase 2
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Start of enrollment: 2009 Nov 01
Completed
Phase 2
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Start of enrollment: 2011 Aug 01
Terminated
Phase 1, Phase 2
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 Sep 01
Completed
Phase 3
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Start of enrollment: 2014 Oct 02
Completed
Phase 1, Phase 2
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

436 citations
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
Sandra P. D'Angelo, Michelle R. Mahoney, Brian A. Van Tine, James N. Atkins, Mohammed M. Milhem
The Lancet. Oncology. 2018-03-01
246 citations
Sorafenib for Advanced and Refractory Desmoid Tumors.
Mrinal M. Gounder, Michelle R. Mahoney, Brian A. Van Tine, Vinod Ravi, Steven Attia
The New England Journal of Medicine. 2018-12-20
2 citations
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.
Patrick Schöffski, Rastislav Bahleda, Andrew J Wagner, Melissa A Burgess, Niels Junker
Clinical Cancer Research. 2023-09-01

Lectures

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced...
2019 ASCO Annual Meeting - 6/1/2019
Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial gia...
2019 ASCO Annual Meeting - 6/1/2019
Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical StudyApril 6th, 2023
CTOS 2022 Annual Meeting: A Phase 1/2 Study of CFT8634 Trial-in-Progress PosterNovember 18th, 2022
Memorial Sloan Kettering Cancer Center Launches New Center to Expand Commitment to Meeting the Unique Needs of Adolescents and Young Adults with CancerSeptember 21st, 2021
Join now to see all

Insurance Accepted

BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Health Net Oregon PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment